Of note, evaluating the effector function of CLA+ T cells activated by clinically relevant triggers of AD has allowed the stratification of patients based on the production of interleukin (IL)-9, IL-13 and IL-31 and in relation to their clinical status [16,17,18]. This evidence concerns the gene IL31 and Alzheimer disease.